论文部分内容阅读
目的:比较局灶进展性胃癌(LAGC)术前与术后行以多西紫杉醇为基础的辅助化疗的疗效。方法:将2011年2月—2012年2月间确诊为LAGC的患者72例随机均分为观察组和对照组。观察组行术前化疗,而对照组则行术后化疗。两组治疗后随访12个月,对比两组手术化疗周期、手术切除率、病理学缓解情况,以及两组不良反应和并发症情况和再次手术情况。结果:两组共行化疗189个周期,其中观察组占比62.43%(118/189),对照组为37.57%(71/189);观察组化疗1个周期者占4.24%(5/118),对照组为22.54%(16/71),差异均有统计学意义(均P<0.05)。观察组完全反应率为27.78%(10/36),部分反应率为63.89%(23/36),对照组为8.33%(3/36),38.89%(14/36),差异均有统计学意义(均P<0.05)。两组手术切除率及淋巴结清扫情况差异均无统计学意义(均P>0.05)。观察组中不良反应发生率低于对照组(P<0.05),但两组间术后并发症发生率及再次手术情况差异均无统计学意义(均P>0.05)。结论:LAGC在术前行以多西紫杉醇为基础的辅助化疗可明显改善治疗效果,同时患者耐受性较好,不良反应少。
Objective: To compare the efficacy of docetaxel-based adjuvant chemotherapy in preoperative and postoperative patients with focal progressive gastric cancer (LAGC). Methods: 72 patients diagnosed as LAGC between February 2011 and February 2012 were randomly divided into observation group and control group. The observation group received preoperative chemotherapy while the control group received postoperative chemotherapy. The two groups were followed up for 12 months after treatment. The two groups were compared in terms of operation and chemotherapy cycle, surgical resection rate, pathological remission, as well as two groups of adverse reactions and complications and reoperation. Results: The two groups were treated with 189 cycles of chemotherapy, accounting for 62.43% (118/189) in the observation group and 37.57% (71/189) in the control group, 4.24% (5/118) in the observation group in one cycle of chemotherapy, , And the control group was 22.54% (16/71), the differences were statistically significant (all P <0.05). The complete response rate in the observation group was 27.78% (10/36), the partial response rate was 63.89% (23/36), and the control group was 8.33% (3/36) and 38.89% (14/36) respectively. The differences were statistically significant Significance (all P <0.05). There was no significant difference in the resection rate and lymph node dissection between the two groups (all P> 0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P <0.05), but there was no significant difference in the incidence of postoperative complications or reoperation between the two groups (all P> 0.05). Conclusion: Preoperative LAGC with docetaxel-based adjuvant chemotherapy can significantly improve the treatment effect, while patients with better tolerance, fewer adverse reactions.